Carregant...

Quantitative risk-benefit analysis of natalizumab

OBJECTIVE: To model the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis (MS). METHODS: We created a Markov model to evaluate treatment effects on reducing relapses and slowing disease progression using published natural history data and clinical trial res...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Thompson, J P., Noyes, K, Dorsey, E R., Schwid, S R., Holloway, R G.
Format: Artigo
Idioma:Inglês
Publicat: American Academy of Neurology 2008
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2676947/
https://ncbi.nlm.nih.gov/pubmed/18663181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/01.wnl.0000319648.65173.7a
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!